Akebia Therapeutics Inc
SWB:AX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Akebia Therapeutics Inc
SWB:AX9
|
US |
|
A
|
Altria Group Inc
LSE:0R31
|
US |
|
G
|
General Dynamics Corp
SWB:GDX
|
US |
|
Geberit AG
F:GBRA
|
CH |
|
C
|
Credit Suisse Group AG
XHAM:CSX
|
CH |
|
C
|
Cheesecake Factory Inc
F:CF2
|
US |
|
W
|
Western Alliance Bancorp
F:WEA
|
US |
|
Regional Management Corp
NYSE:RM
|
US |
Wall St Price Targets
AX9 Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AX9 is 3.7 EUR with a low forecast of 2.62 EUR and a high forecast of 5.45 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is AX9's stock price target?
Price Target
3.7
EUR
According to Wall Street analysts, the average 1-year price target for AX9 is 3.7 EUR with a low forecast of 2.62 EUR and a high forecast of 5.45 EUR.
What is the Revenue forecast for Akebia Therapeutics Inc?
Projected CAGR
-4%
The compound annual growth rate for Revenue over the next 3 years is -4%.
What is the Gross Profit forecast for Akebia Therapeutics Inc?
Projected CAGR
-1%
The compound annual growth rate for Gross Profit over the next 3 years is -1%.
